Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn’s disease: Need for a multidisciplinary approach

Kaynakça (1)

1. Peluso R, Iervolino S, Vitiello M, et al. Articular and other immune-mediated extra-intestinal manifestations in inflammatory bowel diseases. Eur J Inflamm 2014; 12: 251-9. [CrossRef] Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2016; 10: 239-54. [CrossRef] Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85. [CrossRef] Tremblay L, de Chambrun GP, Vroey BD, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohn’s Colitis 2011; 5: 457-60. [CrossRef] Endorf FW, Cancio LC, Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res 2008; 29: 706-12. [CrossRef] Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85. [CrossRef] Goodman H. Nikolsky sign; page from notable contributors to the knowledge of dermatology. AMA Arch Derm Syphilol 1953; 68: 334- 5. [CrossRef]